Stock News•5 days ago
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BridgeBio's infigratinib received FDA priority review for achondroplasia, potentially becoming the first approved oral therapy for the condition.
MarketLens
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI
7 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•3 weeks ago
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed's ARIKAYCE sNDA for MAC lung disease received FDA priority review with a PDUFA date of January 28, 2027, based on positive Phase 3b ENCORE results. Full approval could expand use earlier in tre...
Stock News•2 months ago
Here's Why You Should Add Savara Stock to Your Portfolio Now
Savara (SVRA) advanced Molbreevi after positive long-term phase III data, an on-track FDA review, and expanded patent protection, supporting its commercial outlook.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Stock News•1 hour ago
Why the Market Dipped But Microsoft (MSFT) Gained Today
Stock News•1 hour ago
Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Stock News•1 hour ago
Tesla (TSLA) Declines More Than Market: Some Information for Investors
Stock News•1 hour ago